Target intelligence / Profile preview

Vascular endothelial growth factor receptor tyrosine kinase domain (VEGFR TK domain)

Target
VEGFR TK domain
Molecular classification
Receptor tyrosine kinase, Enzyme, Receptor
01

Overview

The **vascular endothelial growth factor receptor (VEGFR) tyrosine kinase domain** is an intracellular catalytic region present in VEGFR-1, VEGFR-2, and VEGFR-3, which are receptor tyrosine kinases crucial for mediating vascular endothelial growth factor (VEGF)-driven signaling. This domain typically exists in a ‘split’ configuration, with N- and C-terminal lobes separated by an insert sequence, and contains key motifs—such as a glycine-rich ATP-binding loop, a catalytic HRD motif, and an activation loop with a DFG motif—that regulate kinase activity. The kinase domain is essential for initiating downstream signaling that controls endothelial cell proliferation, survival, migration, and blood vessel formation. Inhibitors targeting this domain block ATP binding and receptor autophosphorylation, providing a key strategy in anti-angiogenic therapies for cancers and other diseases characterized by pathological angiogenesis[1][2][3]. Note: To reference a true canonical target, use the full receptor such as "Vascular endothelial growth factor receptor 2 (VEGFR-2, KDR)" for structured ontologies. The tyrosine kinase domain itself is an essential region but not separately drugged outside the context of the full protein.

Other names
VEGFR TK domainVEGF receptor tyrosine kinase domainVEGFR-2 kinase domain (if context clarifies)
02

Mechanism of action

Inhibition of ATP binding at the kinase domain to block receptor phosphorylation and downstream signaling Allosteric inhibition of kinase activity Prevention of receptor activation and dimerization

03

Biological functions

Signal transductionCell proliferationMigrationMetabolismVasodilationBlood vessel formation (angiogenesis)Blood vessel remodeling
04

Disease associations

CancerCardiovascular diseaseOther disorders with abnormal angiogenesis
05

Safety considerations

HypertensionHemorrhageProteinuriaImpaired wound healingCardiotoxicityThromboembolic events
06

Interacting drugs

Sorafenib

7 more in the full profile.

07

Biomarkers

Phosphorylation status of VEGFR (mainly VEGFR-2) in tumor or endothelial tissueCirculating VEGF levelsOther angiogenesis-related markers

Beyond the preview

Go deeper on Vascular endothelial growth factor receptor tyrosine kinase domain (VEGFR TK domain).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Vascular endothelial growth factor receptor tyrosine kinase domain (VEGFR TK domain).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call